Zidesamtinib demonstrates 93% response rate in ROS1-positive lung cancer
New results from the global phase 1/2 ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI). The findings were presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
